Novartis
Novartis reveals strong long-term data Cosentyx in psoriasis of the hands and feet
December 1, 2017Medical Communications, Research and Development Cosentyx, Novartis, palmoplantar psoriasis, pharma, psoriasis
Novartis has released new data for Consentyx (secukinumab) which it claims make the IL-17A inhibitor “the first biologic to show …
Trio, including former Novartis exec, accused of bribery to the tune of over HK$1.5 million
November 28, 2017Manufacturing and Production, Sales and Marketing Novartis, bribery, illegal
A trio, including a former Senior Medical Representative at Novartis, have been charged over allegedly conspiring to offer and accept …
Regeneron forced to drop Eylea combo, advantage Novartis
November 27, 2017Manufacturing and Production, Research and Development Eylea, Novartis, Regeneron, biotech, drugs, pharma, pharmaceutical
Novartis released Phase 3 data on its leading candidate for wet age-related macular degeneration (AMD) drug and it caused a …
Novartis’s Tasigna scores EU approval in paediatric patients
November 20, 2017Sales and Marketing Europe, Novartis, Tasigna, chronic myeloid leukaemia, pharma
Novartis’s Tasigna (nilotinib) has received European Commission approval for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in …
NICE approves Novartis and Pfizer’s rival breast cancer drugs
November 16, 2017Sales and Marketing Kisqali, Novartis, Pfizer, biotech, drugs, ibrance, pharma, pharmaceutical
NICE has announced that it has given the nod to two new treatments for breast cancer with the approval of …
Novartis targets specific patient population with strong Ilaris Phase 3 data
November 14, 2017Manufacturing and Production, Research and Development Ilaris, Novartis, cardiovascular, heart attack, heart disease, pharma
Novartis has presented new Phase 3 data on its cardiovascular drug Ilaris (canakinumab) which demonstrate particular efficacy in a specific …
Seqirus announces £40m UK fill-and-finish flu vaccine facility
November 9, 2017Manufacturing and Production Liverppol, Novartis, UK, Vaccine, flu, influenza, pharma, seqirus
Seqirus, an influenza vaccine specialist subsidiary of global biotech firm CSL, has announced a £40 million investment into a new …
Novartis’ Kisqali smashes Phase 3 primary endpoint in breast cancer for second time
November 8, 2017Research and Development Cancer, Kisqali, Novartis, breast cancer, pharma
Novartis has revealed that its immunotherapy drug Kisqali (ribociclib) met its primary endpoint of progression-free survival in its second Phase …
Novartis aims for CAR-T double-approval in Europe
November 6, 2017Sales and Marketing CAR-T, Gilead, Juno, Novartis, biotech, drugs, pharma, pharmaceutical
Just last week Novartis revealed it had applied to the FDA for a new indication in diffuse large B-cell lymphoma …
Novartis reveals the data behind its showdown with Gilead
November 1, 2017Research and Development CAR-T, Gilead, Kymriah, Novartis, biotech, drugs, pharma, pharmaceutical
Only yesterday it was revealed that Novartis had applied to the FDA in the same indication that Gilead’s treatment is …
CAR-T is bringing true precision to the fight against cancer
November 1, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Gilead, Kymriah, Novartis, Yescarta
Matt Fellows investigates how the first-ever CAR-T therapy approvals in the past months could mean the field of cancer treatment …
Novartis submits second FDA application for CAR-T therapy Kymriah, this time in diffuse large B-cell lymphoma
October 31, 2017Manufacturing and Production, Sales and Marketing CAR-T, Kymriah, Novartis
Following the “historic” FDA approval of the company’s CAR-T therapy Kymriah (tisagenlecleucel) in the treatment of paediatric and young adults …
Novartis to bolster oncology portfolio with $3.9 billion acquisition
October 30, 2017Sales and Marketing Advanced Acclerator Applications, Lutathera, Novartis, pharma
Novartis has announced its intention to acquire France’s Advanced Accelerator Applications (AAA) for $3.9 billion in a move to reinforce …
Novartis Q3: Jimenez talks up Alcon, Gleevec takes generic hammering
October 24, 2017Manufacturing and Production, Sales and Marketing Novartis, biotech, drugs, pharma, pharmaceutical
Novartis released its Q3 financials and, despite Gleevec dipping significantly due to generic competition, still managed to report sales of …
Novartis sheds generics plant and 450 jobs amid pricing pressure
October 18, 2017Manufacturing and Production, Research and Development Novartis, US, closure, generics, manufacturing, pharma
Novartis has announced its intention to shut down its US generics manufacturing plant in Broomfield, Colorado, a move that will …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
